These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 27913927

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y, Shi T, Jiang R, Yin S, Wang P, Zang R.
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [Abstract] [Full Text] [Related]

  • 7. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 8. Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    Chung YS, Kim YJ, Lee I, Lee JY, Nam EJ, Kim S, Kim SW, Kim YT.
    PLoS One; 2017 Sep 11; 12(9):e0183754. PubMed ID: 28873393
    [Abstract] [Full Text] [Related]

  • 9. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.
    Ann Surg Oncol; 2014 Feb 11; 21(2):629-36. PubMed ID: 24052318
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.
    J BUON; 2015 Feb 11; 20(3):847-54. PubMed ID: 26214639
    [Abstract] [Full Text] [Related]

  • 12. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
    Xiao Y, Xie S, Zhang N, Wang J, Lv C, Guo J, Yang Q.
    Gynecol Obstet Invest; 2018 Feb 11; 83(3):209-219. PubMed ID: 29402804
    [Abstract] [Full Text] [Related]

  • 13. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H, Japan Clinical Oncology Group.
    Eur J Cancer; 2016 Sep 11; 64():22-31. PubMed ID: 27323348
    [Abstract] [Full Text] [Related]

  • 14. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb 11; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
    Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A.
    Ann Surg Oncol; 2015 Dec 11; 22 Suppl 3():S952-8. PubMed ID: 26036187
    [Abstract] [Full Text] [Related]

  • 16. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.
    Int J Gynecol Cancer; 2014 May 11; 24(4):687-96. PubMed ID: 24662134
    [Abstract] [Full Text] [Related]

  • 17. The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).
    Wang Q, Liu H, Shen Y, Shen L, Li J, Feng W.
    J Ovarian Res; 2024 Jul 12; 17(1):145. PubMed ID: 38997720
    [Abstract] [Full Text] [Related]

  • 18. Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    Kim NK, Suh DH, Kim K, Kim YB, No JH.
    PLoS One; 2023 Jul 12; 18(4):e0284753. PubMed ID: 37083873
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
    Nagao S, Tamura J, Shibutani T, Miwa M, Kato T, Shikama A, Takei Y, Kamiya N, Inoue N, Nakamura K, Inoue A, Yamamoto K, Fujiwara K, Suzuki M.
    Int J Clin Oncol; 2023 Jun 12; 28(6):804-815. PubMed ID: 37140771
    [Abstract] [Full Text] [Related]

  • 20. Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study.
    Lim H, Bang SH, Kim Y, Cho SH, Shin W, Kim SI, Kim TH, Suh DH, Lim MC, Kim JW.
    BMC Cancer; 2022 Jun 27; 22(1):703. PubMed ID: 35761211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.